DeepMed Research

Naltrexone

Generic Name: Naltrexone

Brand Names: Contrave, Embeda, Vivitrol

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₃NO_₄

CAS Number: 16590-41-3

Unique Ingredient Identifier: 5S6W795CQM

Background: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Indication: Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.

Associated Conditions: Alcohol Dependency, Cholestatic pruritus, Obesity, Opioid Dependence, Severe Pain

Clinical Trials

Inpatient Single Dose Interventions for Alcohol Use Disorder

Early Phase 1

Completed

Conditions: Alcohol Use Disorder, Severe

Interventions: Drug: Ketamine Hydrochloride
Drug: Naltrexone 380 MG
Behavioral: Enhanced linkage

First Posted Date: 2020-09-24

Last Posted Date: 2024-05-02

Lead Sponsor: Denver Health and Hospital Authority

Target Recruit Count: 44

Registration Number: NCT04562779

Locations: 🇺🇸
Denver Health Medical Center, Denver, Colorado, United States

Relapse Prevention in Stimulant Use Disorder

Early Phase 1

Withdrawn

Conditions: Stimulant Use
Relapse
Cognitive Function
ADHD

Interventions: Drug: Contrave 8Mg-90Mg Extended-Release Tablet
Drug: Bupropion

First Posted Date: 2020-09-17

Last Posted Date: 2023-09-22

Lead Sponsor: University of California, Los Angeles

Registration Number: NCT04553263

Locations: 🇺🇸
University of California Los Angeles, Los Angeles, California, United States

Naltrexone Treatment for Prolonged Grief Disorder (PGD)

Phase 4

Terminated

Conditions: Prolonged Grief Disorder

Interventions: Drug: Naltrexone HCl 50 MG Oral Tablet
Drug: Placebo

First Posted Date: 2020-09-14

Last Posted Date: 2024-08-28

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 9

Registration Number: NCT04547985

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

LDN and tDCS in Fibromyalgia

Phase 2

Completed

Conditions: Fibromyalgia

Interventions: Drug: Placebo
Drug: Low-Dose Naltrexone
Device: Sham Transcranial Direct Current Stimulation
Device: Transcranial Direct Current Stimulation

First Posted Date: 2020-08-06

Last Posted Date: 2020-08-06

Lead Sponsor: Centro Universitario La Salle

Target Recruit Count: 92

Registration Number: NCT04502251

Locations: 🇧🇷
Universidade La Salle, Canoas, Rio Grande Do Sul, Brazil

Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study

Phase 2

Completed

Conditions: Overweight or Obesity
Breast Cancer

Interventions: Drug: Contrave
Behavioral: Behavioral Weight Loss

First Posted Date: 2020-08-05

Last Posted Date: 2025-03-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 53

Registration Number: NCT04499950

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Phase 2

Recruiting

Conditions: Opioid Use Disorder (OUD)

Interventions: Drug: SL-BUP
Drug: XR-BUP
Drug: XR-NTX
Behavioral: MM
Behavioral: MMR
Behavioral: MMD

First Posted Date: 2020-07-09

Last Posted Date: 2025-05-14

Lead Sponsor: NYU Langone Health

Target Recruit Count: 2190

Registration Number: NCT04464980

Locations: 🇺🇸
University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST), Little Rock, Arkansas, United States
🇺🇸
Tarzana Treatment Centers, Inc., Tarzana, California, United States
🇺🇸
Liberation Programs, Inc., Bridgeport, Connecticut, United States

and more 17 locations

Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder

Phase 2

Not yet recruiting

Conditions: Opioid Dependence

Interventions: Drug: Vivitrol
Drug: Brixadi

First Posted Date: 2020-07-01

Last Posted Date: 2024-11-01

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 200

Registration Number: NCT04454411

Low-dose Naltrexone for Bladder Pain Syndrome

Phase 2

Suspended

Conditions: Bladder Pain Syndrome
Interstitial Cystitis

Interventions: Drug: Placebo
Drug: Naltrexone

First Posted Date: 2020-06-29

Last Posted Date: 2023-12-22

Lead Sponsor: Stanford University

Target Recruit Count: 40

Registration Number: NCT04450316

Locations: 🇺🇸
Stanford Health Care, Stanford, California, United States

Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia

Phase 2

Completed

Conditions: Lichen Planopilaris
Frontal Fibrosing Alopecia

Interventions: Drug: Low-Dose Naltrexone

First Posted Date: 2020-06-01

Last Posted Date: 2021-12-30

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 43

Registration Number: NCT04409041

Locations: 🇺🇸
Washington University, Saint Louis, Missouri, United States

Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail

Phase 2

Active, not recruiting

Conditions: Opioid-use Disorder

Interventions: Drug: XR-B
Drug: XR-NTX

First Posted Date: 2020-05-29

Last Posted Date: 2025-03-07

Lead Sponsor: Friends Research Institute, Inc.

Target Recruit Count: 240

Registration Number: NCT04408313

Locations: 🇺🇸
Friends Research Institute, Baltimore, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy